Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.

[1]  S. de la Motte,et al.  Omalizumab Protects against Allergen- Induced Bronchoconstriction in Allergic (Immunoglobulin E-Mediated) Asthma , 2012, International Archives of Allergy and Immunology.

[2]  N. Hanania,et al.  Targeting IgE in asthma , 2012, Current opinion in pulmonary medicine.

[3]  C. Reynolds,et al.  Bioequivalence of a Novel Omalizumab Solution for Injection Compared with the Standard Lyophilized Powder Formulation , 2011 .

[4]  R. Slavin,et al.  Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. , 2009, The Journal of allergy and clinical immunology.

[5]  S. Tannenbaum,et al.  Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. , 2009, British journal of clinical pharmacology.

[6]  S. Holgate,et al.  Safety and tolerability of omalizumab , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  R. Strunk,et al.  Omalizumab for asthma. , 2006, The New England journal of medicine.

[8]  Dave P. Miller,et al.  High Prevalence of Skin Test Positivity in Severe or Difficult-to-Treat Asthma , 2006, The Journal of asthma : official journal of the Association for the Care of Asthma.

[9]  J. Bousquet,et al.  The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.

[10]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[11]  J. Bousquet,et al.  Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  Charles A. Johnson,et al.  Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma , 2003, Current medical research and opinion.

[13]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .